Exhibit 5.4
![LOGO](https://capedge.com/proxy/8-K/0001193125-19-187797/g762838dsp30.jpg)
Medtronic, Inc.
710 Medtronic Parkway
Minneapolis MN 55432
www.medtronic.com
July 2, 2019
Medtronic, Inc.
710 Medtronic Parkway
Minneapolis, MN 55432
Re: | Medtronic Global Holdings S.C.A. Senior Notes |
Ladies and Gentlemen:
This opinion is furnished to you in connection with the offer and sale by Medtronic Global Holdings S.C.A, an entity organized under the laws of Luxembourg (“Medtronic Luxco”) of €250,000,000 aggregate principal amount of its Floating Rate Senior Notes due 2021 (the “Floating Rate Notes”), €750,000,000 aggregate principal amount of its 0.00% Senior Notes due 2022 (the “2022 Notes”), €1,000,000,000 aggregate principal amount of its 0.25% Senior Notes due 2025 (the “2025 Notes”), €1,000,000,000 aggregate principal amount of its 1.00% Senior Notes due 2031 (the “2031 Notes”), €1,000,000,000 aggregate principal amount of its 1.50% Senior Notes due 2039 (the “2039 Notes”), and €1,000,000,000 aggregate principal amount of its 1.75% Senior Notes due 2049 (the “2049 Notes”, and together with the Floating Rate Notes, the 2022 Notes, the 2025 Notes, the 2031 Notes and the 2039 Notes, the “Notes”), pursuant to the Underwriting Agreement dated June 25, 2019 (the “Underwriting Agreement”), among Medtronic Luxco, the Guarantors (as defined below), Barclays Bank PLC, Merrill Lynch International and Goldman Sachs & Co. LLC, as representatives of the Underwriters party to the Underwriting Agreement. The Notes will be fully and unconditionally guaranteed on an unsecured unsubordinated basis by Medtronic, Inc., a Minnesota corporation (the “Company,” and such guarantee, the “Company Guarantee”) and Medtronic Public Limited Company, an entity incorporated under the laws of Ireland (“Medtronic plc,” and together with the Company, the “Guarantors”).
The Floating Rate Notes will be issued pursuant to the Indenture dated as of March 28, 2017 (the “Base Indenture”), among Medtronic Luxco, the Guarantors and Wells Fargo Bank, National Association, as trustee (the “Trustee”), as supplemented by the Second Supplemental Indenture dated as of March 7, 2019 (the “Second Supplemental Indenture” and together with the Base Indenture, the “Reopening Indenture”) among Medtronic Luxco, the Guarantors, the Trustee and Elavon Financial Services DAC, as the paying agent (the “Paying Agent”). The remaining Notes will be issued pursuant to the Base Indenture as supplemented by the Third Supplemental Indenture dated as of July 2, 2019 (the “Third Supplemental Indenture” and together with the Base Indenture the “New Issue Indenture” and together with the Reopening Indenture, the “Indentures”), among Medtronic Luxco, the Guarantors, the Trustee and the Paying Agent.
Medtronic Luxco, the Company and Medtronic plc have filed with the Securities and Exchange Commission (the “Commission”) a Registration Statement on FormS-3 (FileNo. 333-215895) under the Securities Act of 1933, as amended (the “Act”), on February 6, 2017 (the “Registration Statement”) including the prospectus dated as of February 3, 2017 (the “Base Prospectus”), as supplemented by a preliminary prospectus supplement dated as of June 25, 2019 (the “Preliminary Prospectus Supplement”) relating to the Notes, and a prospectus supplement dated as of June 25, 2019 (the “Prospectus Supplement”) relating to the Notes.